Private equity plastic surgery practices were rare a decade ago. Today, private equity-backed platforms are among the most active buyers of surgical practices, and many surgeon-owners have already had the call. Some see it as the best exit available. Others won’t take the meeting.
Both reactions deserve better information. This guide explains how private equity invests in plastic surgery, what it pays and why, the real trade-offs, what the research says about PE in physician practices, and nine questions to ask before you sell. It supports our main guide to who buys plastic surgery practices.
Key takeaways
- Physician Growth Partners counts ten or more PE-backed plastic surgery platforms, including Athenix, Ascend Plastic Surgery Partners and Olympus Cosmetic Group (PGP).
- PE firms buy a platform, add practices, then sell the larger group. FOCUS describes a five-to-seven-year hold in physician practice deals (FOCUS).
- PE usually pays the highest multiples, but part of the price often comes as rollover equity and earnouts.
- The specific buyer matters more than the label. Vet its fund timeline, debt, surgeon retention and clinical autonomy.
How does private equity invest in plastic surgery practices?
A private equity firm raises a fund, buys a larger practice as a platform through a management services organization, then acquires smaller practices as add-ons to build scale. After several years it sells the combined group, usually to a larger investor. Surgeons who sold typically hold rollover equity and share in that sale.
That cycle drives everything a PE buyer does. It wants growth, systems that can absorb new practices, and surgeons who will stay and help recruit others. It also works on a clock. PitchBook found that the median US private equity hold reached 3.4 years at the end of 2024, the longest in over nine years. A buyer’s position in that cycle shapes its offer.
Why is private equity interested in plastic surgery?
Because demand is growing, most revenue is cash-pay, and the market is fragmented. The American Society of Plastic Surgeons reported cosmetic surgical procedures up 7% in 2025, and most plastic surgery practices remain independently owned. Those conditions suit a buy-and-build strategy.
The ASPS 2025 report showed lift procedures leading growth and patients 66 and older up 24%. Physician Growth Partners’2024 white paper described a heavily fragmented market with most practices still independent. FOCUS Investment Banking reported a 440% increase in plastic surgery deal volume over the two years to 2024.
What do private equity buyers pay for plastic surgery practices?
Usually the highest multiples in the market, especially for larger practices. FOCUS Investment Banking reported 2026 platform deals from 5x to 6x EBITDA under $1 million up to 9x to 12x or more above $7 million, with add-ons at 5x to 9x. Offers typically combine cash at closing, rollover equity and sometimes an earnout.
The mix matters as much as the multiple. A higher headline price paid largely in equity carries risk that a lower cash-heavy offer doesn’t. For how the numbers compare, see our guide to plastic surgery practice EBITDA multiples. For the equity side, see our guide to plastic surgery rollover equity.
Should I sell my plastic surgery practice to private equity?
It can make sense if you want a strong price, capital to grow, help with operations and a potential second payday, and you’re comfortable with a multi-year employment agreement and less independence. It may not suit you if control over marketing, staffing and pricing matters most, or if you plan to retire soon.
| Consideration | Private equity | Surgeon buyer or independence |
| Price | Often highest | Often lower |
| Cash at closing | Large, but part of the price may be equity | Usually all cash or seller financing |
| Second payday | Possible through rollover equity | Unlikely |
| Operating support | Marketing, billing, technology, recruiting | Limited |
| Independence | Reduced; decisions shared with the MSO | Higher |
| Time commitment after sale | Often three to five years | Varies |
How are private equity plastic surgery practices deals structured?
Most use a management services organization. The MSO, owned by the private equity sponsor, buys your practice’s non-clinical assets and goodwill for cash and rollover equity, and signs a long-term management agreement with a physician-owned professional entity that employs you. The structure keeps clinical control with physicians, as state law requires.
Beyond the MSO, the key pieces are the purchase agreement, your employment agreement, the management services agreement and the equity documents for your rollover. Each is negotiated separately, and each affects what you keep. Surgeons at private equity plastic surgery practices often say the employment and management terms mattered as much as the price.
What do private equity buyers look for?
Growth, surgeon depth, recurring non-surgical revenue, strong management, an owned surgical facility, a recognized brand and clean compliance. They also look for surgeon-owners who want to keep operating and help the platform recruit. FOCUS lists revenue diversification, multi-provider depth, ancillary revenue, facility ownership and brand equity among premium drivers.
Buyers also judge fit. A platform building in your region will value your practice more than one with no presence nearby. And they’ll judge you: surgeons who are open about their numbers, realistic about add-backs and clear about their goals tend to get better terms.
What does the research say about private equity plastic surgery practices?
Research is mixed and still developing, and most of it covers other specialties. The Milbank Memorial Fund cites studies finding price increases of about 11% after PE acquisitions in dermatology, gastroenterology and ophthalmology. Other research has looked at changes in industry relationships. Direct studies of plastic surgery are limited.
The Milbank Memorial Fund also reports non-hospital corporate entities now employ or affiliate with more physicians than hospitals do, at 30.1% versus 28.4%. A 2025 JAMA Ophthalmology study found 3,129 of 18,672 ophthalmologists it studied were affiliated with private equity between 2016 and 2020. For surgeons, the takeaway is to understand how a buyer operates, not to assume every PE deal is the same.
9 smart questions to ask a private equity buyer
The best private equity plastic surgery practices partnerships start with hard questions. Ask each of these, get the answers in writing where you can, and compare them across buyers.
1. When the fund was raised and when it plans to sell
A buyer early in its hold plans differently from one preparing to exit next year. This affects your rollover equity timing.
2. How much debt the platform carries
Debt sits ahead of equity. More debt means the platform needs more growth for your stake to gain value.
3. How surgeon pay is calculated after the sale
Get the formula in writing and model it over several years, including what happens if the practice grows or shrinks.
4. Which clinical decisions stay with you
Procedures, patient selection, clinical staffing and medical records should stay with physicians. State laws, like California’s SB 351, reinforce this.
5. Who approves marketing and pricing
In aesthetic surgery, marketing drives growth. Know who decides and who’s accountable for claims.
6. How many surgeons have left, and why
Retention tells you more than any pitch deck. Ask for references from surgeons who stayed and, if possible, from some who left.
7. What happens to your staff
Ask about wages, benefits, titles and which functions will be centralized.
8. How your rollover equity will be treated
Which entity, which class of units, what preferences sit ahead of you, and what happens if you leave early.
9. What the non-compete looks like
Length, radius and what happens if you’re terminated without cause. State laws on physician non-competes vary widely.
When is private equity the wrong choice?
When you plan to stop operating within a year or two, when independence over marketing and pricing matters more than price, or when the specific buyer can’t answer basic questions about its debt, surgeon retention and exit timeline. In those cases, a surgeon buyer, an internal successor or simply waiting may serve you better.
Timing can also be wrong. Selling while your practice is still heavily dependent on you usually means a lower multiple and a longer employment commitment. A year or two spent adding an associate and cleaning up your numbers can change both.
How do you run a process with private equity buyers?
Confidentially and competitively. Approach several qualified buyers at once under NDAs, including private equity platforms, other surgeon buyers and aesthetics groups, so you can compare real offers. A single inbound PE offer shows you one buyer’s view. Several reveal your practice’s real value and give you bargaining power on terms.
An experienced advisor helps here, because PE buyers negotiate for a living. The letter of intent is where you have the most bargaining power, so settle cash, rollover, compensation, non-compete and clinical autonomy terms there, before exclusivity starts. Our guide to a plastic surgery MSO explains the structure most PE deals use.
What changes at private equity plastic surgery practices after a sale?
You’ll typically keep operating under an employment agreement while the platform integrates your practice into its systems for billing, marketing, purchasing and technology. Your staff usually stay, though some administrative roles may centralize. Several years later, the sponsor sells the platform, and your rollover equity is paid out or rolled again.
That later sale is the second bite of the apple. As more platforms reach the end of their hold periods, more surgeons face that event. Our guide to plastic surgery consolidation covers what the wave of platform sales means for the market.
Frequently asked questions
Is private equity buying plastic surgery practices?
Yes. Physician Growth Partners lists ten or more PE-backed plastic surgery platforms, including Athenix, Inspire Aesthetics, Ascend Plastic Surgery Partners and Olympus Cosmetic Group. FOCUS Investment Banking reported a 440% increase in plastic surgery deal volume over the two years to 2024, and buyers expect continued activity.
How much do private equity firms pay for plastic surgery practices?
FOCUS Investment Banking reported 2026 platform deals at 5x to 12x or more EBITDA depending on size, and add-ons at 5x to 9x. Offers usually combine cash at closing with rollover equity and sometimes an earnout, so compare the guaranteed cash as well as the headline number.
What are the downsides of selling to private equity?
Less independence, a multi-year employment agreement, a non-compete, integration into the buyer’s systems and rollover equity that could lose value if the platform struggles or carries heavy debt. Some surgeons also dislike centralized marketing or pricing. Vetting the specific buyer carefully reduces these risks.
How long do private equity firms keep plastic surgery practices?
Usually several years. FOCUS describes a five-to-seven-year hold period in physician practice deals, and PitchBook reported the median US private equity hold reached 3.4 years at the end of 2024. After that, the sponsor typically sells the platform to a larger investor or strategic buyer.
Do I have to keep working after selling to private equity?
Almost always, for a period. PE buyers want the selling surgeon to keep operating, and TUSK Practice Sales reports employment agreements typically run three to five years. Your compensation, schedule, clinical autonomy and exit terms are negotiated before closing, so settle them in the letter of intent.
Can I sell to private equity and still keep some ownership?
Yes. Most PE deals include rollover equity, where you reinvest part of your price in the buyer’s company. You become a minority owner and share in the value if the platform is later sold. Understand the class of equity, the debt ahead of it and the vesting terms.
Private equity plastic surgery practices: the bottom line
Private equity plastic surgery practices deals can deliver a strong price, operating support and a second payday, with real trade-offs in independence and risk. The label matters less than the specific buyer. Ask hard questions, compare several offers and negotiate the whole deal before you sign.
| Been approached by a private equity buyer? Get the Plastic Surgery Exit Report newsletter for quarterly buyer updates, or book a confidential conversation with the plastic surgery team at Olympic M&A before you respond. Disclosure: Plastic Surgery Exit Report is published in partnership with Olympic M&A, a healthcare M&A advisory firm. |
